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Abstract 
 
Chronic hepatitis C virus (HCV) infection is associated with several extra-hepatic 
manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae, 
ranging from cutaneous and visceral vasculitis to glomerulonephritis and B cell non-Hodgkin’s 
lymphoma. HCV-infected patients have increased rates of insulin resistance, diabetes and 
atherosclerosis, which may lead to increased cardiovascular morbidity and mortality. Neurologic 
manifestations of HCV infection include fatigue and cognitive impairment. The mechanisms 
causing the extra-hepatic effects of HCV infection are likely multifactorial and may include 
endocrine effects, HCV replication in extra-hepatic cells, or a heightened immune reaction with 
systemic effects. Successful eradication of HCV with interferon alpha and ribavirin was shown to 
improve some of these extra-hepatic effects: sustained virologic response is associated with 
resolution of complications of cryoglobulinemia, reduced levels of insulin resistance, reduced 
incidence of diabetes and stroke, and improved fatigue and cognitive functioning. The 
availability of new interferon-free, well-tolerated anti-HCV treatment regimens is broadening the 
spectrum of patients available for therapy, including those in whom interferon was 
contraindicated, and will likely result in greater improvements in the extra-hepatic manifestations 
of HCV. If these regimens are shown to confer significant benefit in the metabolic, 
cardiovascular, or neuropsychiatric conditions associated with HCV infection, extra-hepatic 
manifestations of HCV may become a major indication for treatment even in the absence of liver 
disease.  
 
Key words: cryoglobulins, insulin resistance, cardiovascular risk, fatigue, health-related quality 
of life
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Introduction 
Treating patients chronically infected with hepatitis C virus (HCV) to eradicate the infection and 
achieve sustained virologic response (SVR; undetectable HCV RNA 12 or 24 weeks after the 
completion of therapy) decreases the risk of cirrhosis, liver failure, and hepatocellular carcinoma 
(HCC).1-3 In addition to liver-related sequelae, chronic HCV infection is associated with changes 
in organ systems outside the liver, including metabolic, cardiovascular, and neurologic systems, 
and with autoimmune and immune-mediated conditions such as mixed cryoglobulinemia, thyroid 
disease, and glomerulonephritis.4-7 A large, prospective cohort study found that patients with 
chronic HCV infection, defined as having detectable HCV RNA in the serum, have an elevated 
risk of death from both hepatic and non-hepatic diseases, including cardiovascular and renal 
diseases, compared with uninfected patients and those with anti-HCV but no detectable HCV 
RNA in serum.8 These and other findings raise the question of whether successful treatment of 
chronic HCV may also improve the associated extra-hepatic effects and reduce non-hepatic 
morbidity and mortality. One multicenter international study has already demonstrated that 
achieving SVR reduces not only liver-related but also all-cause and non-liver-related mortality.9  
 
The mechanisms causing the extra-hepatic effects of HCV are incompletely understood. HCV 
drives clonal expansion of B cells10, 11 to generate IgM rheumatoid factor in susceptible 
individuals that results in immune complex deposition in small vessels and a vasculitis, although 
susceptibility factors are unknown. The mechanisms of other manifestations are multifactorial, 
including a direct interaction between viral proteins and intracellular signaling pathways, or viral 
replication in extra-hepatic cells, or a heightened immune reaction with systemic effects. 
Immune activation may lead to a chronic inflammatory state that can affect a number of 
systems, as has been observed in HIV infection.12 Like HIV, HCV infection is associated with a 
decreased quality of life,13 with fatigue, depression and cognitive impairment being the most 
important drivers.14 There is evidence that treatment to eradicate HCV infection may improve 
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some extra-hepatic manifestations of HCV independently of the severity of the underlying liver 
disease. The evidence is strongest for mixed cryoglobulinemia, which often resolves entirely 
with viral clearance.15-17 
 
In the era of interferon-based treatment, extra-hepatic manifestations of HCV were frequently 
regarded as contraindications to treatment because the treatments could exacerbate them, or 
because ongoing treatment of coexisting extra-hepatic syndromes may have resulted in 
untoward drug–drug interactions or additional toxicities. Patients with a history of autoimmune 
disease or psychological instability, for example, are often ineligible for interferon-containing 
regimens.18, 19 Recent advances in anti-HCV therapy have led to well-tolerated, interferon-free 
regimens, such that more patients may be treated, leading to the potential for improvements in 
extra-hepatic manifestations on a larger scale. While previously, quality of life decreased during 
antiviral therapy, interferon-free therapies may improve quality of life while patients are on 
treatment,20, 21 and allow treatment where previously contra-indicated.22 This review will consider 
the impact of chronic HCV infection on sites outside the liver, focusing on immunological, 
metabolic, cardiovascular, and neurologic manifestations. 
 
Metabolic manifestations of HCV infection 
Diabetes mellitus and insulin resistance 
Several studies have shown that patients with chronic HCV infection have an increased risk of 
diabetes mellitus compared with uninfected individuals (Table 1).5, 6, 23 White and co-workers 
showed that HCV infection is associated with an increased risk of diabetes in comparison to 
both uninfected and hepatitis B virus (HBV)-infected controls, suggesting that HCV plays a 
specific role in conferring the increased diabetes risk.24 The elevated risk is likely due to an 
association between HCV and insulin resistance. Recent data suggest that HCV-induced liver 
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inflammation may significantly increase this risk, 25, 26, and the observation that increased levels 
of liver enzymes, rather than HCV infection, is the true risk factor of diabetes development in the 
HCV-infected US population27 should be interpreted in view of the above findings. 
 
HCV-infected patients have significantly higher levels of insulin resistance (as measured by the 
homeostasis model for assessment of insulin resistance [HOMA-IR]) than uninfected controls or 
HBV-infected patients matched for BMI, waist circumference, age, and sex (Table 1).28, 29 
However, the evidence in favor of a viral dose-effect is weak: although patients with higher viral 
load tend to have higher levels of insulin resistance,29-31 the correlation between HOMA-IR score 
and HCV RNA levels is on average very weak or absent.32, 33 Similarly, there is no consistently 
reported genotype-specificity associated with HOMA-IR levels.34-37 
 
The most compelling evidence that HCV causes insulin resistance is the observation that curing 
HCV with antiviral therapy results in reduced levels of insulin resistance, while levels remain 
unchanged in virologic non-responders38. A phase 1 study of an interferon-free, short course of 
danoprevir, an inhibitor of the HCV non-structural 3 (NS3) serine protease, showed a close 
correlation between viral load decline and reduction of HOMA-IR levels.39 This suggests that 
treatment with HCV protease inhibitors or other anti-HCV DAAs may restore insulin sensitivity in 
chronic HCV-infected patients. 
 
Mechanisms of HCV-induced insulin resistance 
HCV may directly interfere with the insulin signaling pathway. This is suggested by the finding 
that non-obese, non-diabetic, HCV-infected individuals have hepatic insulin resistance, as 
determined by the hyperinsulinemic euglycemic clamp technique. Two different studies showed 
that endogenous glucose production in such patients was incompletely suppressed by low-dose 
insulin.34, 40 In one study, the hepatic insulin resistance index increased by a factor of 3 
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compared with healthy controls.34 When liver samples from HCV-infected patients and 
uninfected controls were challenged with insulin ex vivo, the insulin-induced activation of the 
protein kinase B/Akt, the key kinase responsible for most metabolic effects of insulin, was 
blunted in HCV-infected cells compared with controls.41 According to experimental models, the 
HCV core protein seems sufficient to induce insulin resistance via several post-receptorial 
mechanisms.42    
 
In addition to hepatic insulin resistance, however, peripheral insulin resistance is also elevated 
in HCV infection, and appears to be the most important component of HCV-associated whole 
body insulin resistance34, 40. An increased peripheral insulin resistance was reported 
independently by the above cited two groups who used a hyperinsulinemic euglycemic clamp in 
non-obese, normoglycemic, HCV-infected patients.34, 40 Using high insulin concentrations, 
glucose uptake and oxidative consumption were impaired, implying a deficient glucose transport 
and disposal, accounted for by striated muscle. Interestingly, this viral-associated insulin 
resistance does not appear to involve increased free fatty acid efflux from adipose tissue, which 
remains normally sensitive to insulin.34, 40 Thus, glucose uptake is clearly impaired in patients 
with HCV infection. 
 
Finally, the HCV-induced liver inflammation25, 26 may increase the risk of developing IR via the 
release of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin-6, 
which may in turn interfere with the insulin signaling transduction pathway in hepatocytes.43  
 
In summary, HCV causes hepatic and extra-hepatic insulin resistance. While hepatic 
impairment of insulin effects may be mediated by direct interactions within infected hepatocytes, 
increased peripheral insulin resistance may be caused by endocrine effects of soluble mediators 
secreted by infected hepatocytes. These soluble mediators may also increase hepatic insulin 
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resistance via paracrine mechanisms. They may exert their peripheral effects by reducing 
glucose uptake and oxidative consumption by extra-hepatic tissues, specifically muscle, and 
probably to a lesser extent, adipose tissue.34, 40 The factors involved in the paracrine and 
endocrine propagation of insulin resistance are currently unknown. In addition to TNF-α, other 
candidate cytokines include interleukin-8,44, 45 chemokine (C-C) motif ligand 2 (CCL2),45 
interleukin-18,34 chemerin46 and visfatin.47 
 
Insulin resistance and outcomes 
HCV-associated insulin resistance correlates with poor outcomes, including accelerated 
progression of hepatic fibrosis, reduced SVR rates, and the development of HCC, and of type 2 
diabetes and its cardiovascular sequelae.48-51 There is no clear evidence that insulin resistance 
promotes HCV replication: treatment of chronic HCV with insulin sensitizers such as 
pioglitazone reduced insulin resistance, but failed to reduce viremia.52 However, among chronic 
HCV-infected patients with minimal or no fibrosis (F0–F1), the HOMA-IR score was 
independently associated with the progression of fibrosis.48 Higher HOMA-IR scores have also 
been shown to be associated with lower SVR rates in patients treated with interferon, 
independently of HCV genotype.49, 50, 53-55 Finally, a large retrospective study showed that 
among HCV-infected patients, the presence of type 2 diabetes increases the incidence of HCC 
nearly two-fold compared with non-diabetic patients.56 Controlling glycemia seems to make a 
difference: a higher incidence of HCC occurred in patients with HbA1c ≥7% than among those 
with HbA1c <7%. 
 
In contrast to its effect on outcomes with interferon-based treatment, insulin resistance appears 
to have no effect on outcomes following treatment with DAAs. A study of danoprevir 
monotherapy showed that the rate of HCV RNA decline was not associated with baseline 
HOMA-IR scores,39 and two studies using telaprevir-based regimens showed that HOMA-IR 
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scores failed to predict virologic endpoints, including SVR.57, 58 However, telaprevir-based 
regimens still contain peginterferon and ribavirin. The availability of DAAs may enable the 
successful treatment of more HCV-infected patients, since even those previously classified as 
difficult-to-treat due to baseline insulin resistance may have improved outcomes with new 
therapies that do not include interferon. 
 
Cardiovascular manifestations of HCV infection 
HCV as a cardiovascular risk factor 
Despite the association of HCV with insulin resistance, type 2 diabetes, and hepatic steatosis, it 
is still unclear whether HCV is an independent risk factor for cardiovascular disease.59 HCV-
infected patients have significantly lower levels of total cholesterol, low-density lipoprotein, and 
triglycerides, and higher levels of high-density lipoprotein, than uninfected individuals,60, 61 thus 
demonstrating what has been called a cardioprotective lipid profile. Nevertheless, data from 
several studies show an association between HCV infection and atherosclerotic changes. A 
case-control study showed that the prevalence of HCV positivity was significantly higher among 
patients with angiographically documented coronary artery disease (>50% stenosis) than 
among controls (patients hospitalized for other cardiac abnormalities), and that the HCV 
prevalence increased with the number of arteries affected.62 On multivariate analysis, HCV 
seropositivity was identified as an independent predictor of coronary artery disease, with an 
odds ratio of 4.2 (95% CI 1.4–13.0). Another study showed that HCV infection is an independent 
predictor of coronary atherosclerosis severity, with an odds ratio of 2.0 (95% CI 1.6–2.6).63 
Studies of changes in the carotid arteries have yielded similar results, showing an association of 
HCV infection with early, asymptomatic carotid atherosclerosis, as indicated by carotid intima-
media thickness and the presence of plaques.64, 65 The HCV viral load is independently 
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associated with carotid atherosclerosis, suggesting a causal link between the level of HCV 
infection and atherosclerotic changes.32 Accordingly, a study reported that the risk of peripheral 
artery disease in HCV infection is higher than in uninfected patients, especially in the presence 
of comorbidities.66  
 
Consistent with the association of HCV with atherosclerosis, rates of cardiovascular events and 
mortality may be elevated among HCV-infected patients. A retrospective study of first-time 
blood donors showed increased rates of overall and cardiovascular mortality among anti-HCV-
positive compared with anti-HCV-negative individuals, with a hazard ratio (HR) of 2.21 (95% CI 
1.41–3.46).67 A recent prospective study confirmed these findings, showing that HCV-infected 
patients have increased hepatic and extra-hepatic mortality, including increased mortality from 
circulatory diseases (HR 1.50; 95% CI 1.10–2.03).8 Further, among anti-HCV-positive 
individuals, the increased mortality from circulatory diseases held for patients with detectable 
HCV RNA, but not for those with undetectable HCV RNA, suggesting a causal connection 
between the virus and circulatory mortality. A recent cohort study in Taiwan found that chronic 
HCV infection is an independent predictor of stroke, with an adjusted HR of 1.27 (95% CI 1.14–
1.41), and a community-based prospective study found that chronic HCV infection is an 
independent predictor of cerebrovascular death, with a significant association between 
cerebrovascular mortality and increasing serum HCV RNA levels.68, 69  
 
However, some studies have found no association between HCV infection and cardiovascular 
disease. A large retrospective study in the UK showed no difference in the incidence of acute 
myocardial infarction between HCV-infected and -uninfected patients,70 and a case-control 
study of active-duty US military personnel similarly found no association between HCV and 
myocardial infarction.71 Several cross-sectional and longitudinal studies have demonstrated the 
lack of an independent association of HCV with atherosclerosis incidence or severity.72, 73 The 
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contradictory findings regarding HCV infection and cardiovascular disease may be due to 
differences in the characteristics of populations studied, or in the assessment of endpoints or 
adjustments for confounding factors. In addition, stratification for the prevalence of well known 
cardiovascular risk factors like smoking, diabetes and hypertension could help to better 
understand the reported conflicting results, and to identify groups of patients where the effect of 
HCV on cardiovascular risk is further pronounced. 
 
Potential mechanisms of cardiovascular effects 
The potential association between HCV infection and cardiovascular risk raises the question of 
the mechanism underlying this association. Metabolic factors may play a role: the insulin 
resistance associated with HCV leads to hyperglycemia, endothelial dysfunction, and 
inflammation, all of which produce vessel damage and unstable plaques. Perticone and co-
workers recently demonstrated a significant correlation between insulin resistance and left 
ventricular mass among normotensive patients with HCV infection, and a strong relationship 
between HCV viral load and both of these parameters.74 The presence of HCV may also induce 
a chronic inflammatory state with systemic effects. In support of this, Maruyama and co-
workers, in a myocardial scintigraphy study of HCV-infected patients, found that 87% had 
myocardial perfusion defects, and that the severity of the defects was associated with the 
degree of liver necroinflammatory activity.75 These findings suggest that the pro-inflammatory 
environment leading to necrosis and consequently fibrosis in the liver also has systemic effects, 
leading to atherosclerosis in the vessels. Consistent with this suggestion, Petta and co-workers 
found that severe hepatic fibrosis (F3/F4 vs F1/F2) was independently associated with carotid 
plaque development in HCV patients.65  
 
HCV and cardiovascular outcomes 
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If active HCV infection is associated with cardiovascular risk, then HCV eradication might 
reduce that risk and reduce cardiovascular events. Some studies have demonstrated such a 
connection. In the above-mentioned myocardial scintigraphy study, successful HCV RNA 
suppression during treatment and eradication post-treatment with interferon-based therapy was 
associated with improvements in the baseline myocardial perfusion defects.75 Moreover, among 
patients who relapsed, there was initial improvement during HCV RNA suppression, then 
worsening of the perfusion defects at the time of re-appearance of the virus, while among non-
responders, no change in perfusion defects was observed. Regarding cardiovascular events, a 
large, retrospective cohort study found that interferon-based therapy significantly reduced stroke 
incidence compared with no treatment (adjusted HR 0.39; 95% CI 0.16–0.95),76 suggesting the 
potential long-term extra-hepatic benefits of successfully treating HCV infection. Consistent with 
these results a recent study from Taiwanese patients with HCV infection showed that interferon-
based treatment significantly reduced the incidence of end-stage renal disease, acute coronary 
syndrome, and ischemic stroke.77  
 
Neurologic manifestations of HCV infection 
Neuropsychiatric symptoms associated with HCV 
Chronic HCV infection is associated with psychiatric co-morbidities. Fatigue, depression, 
anxiety, bipolar disorder, and schizophrenia are all more prevalent among HCV-infected 
patients than the general population.78 This is partly related to the higher incidence of risk 
behaviors among persons with psychiatric disorders that can result in HCV exposure and 
increased alcohol use.79 However, emerging literature demonstrates that HCV is also 
associated with an increased prevalence of neuropsychiatric symptoms, independent of pre-
existing mental disorders or high risk behaviors (Table 2). HCV-infected patients have a 
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significantly reduced quality of life, as manifested by physical symptoms including fatigue, 
energy level, and physical functioning, compared with both uninfected and HBV-infected 
controls.80 Moreover, this reduced quality of life could not be attributed to cirrhosis since patients 
with cirrhosis were excluded from the study, and was found to hold true for patients with or 
without a history of substance abuse and with either mild or severe liver necroinflammation. 
Thus, the symptoms causing the reduced quality of life appeared to be due to the presence of 
HCV, regardless of the mode of acquisition of HCV or the severity of liver disease. In 
subsequent larger studies, the mental aspects of health-related quality of life (HRQL) appeared 
specifically impaired in HCV infection compared with primary biliary cirrhosis, in which physical 
well-being was more impaired.81  
 
Fatigue and cognitive impairment have both been associated with HCV infection and are in part 
responsible for the reduced quality of life. Fatigue is the most common symptom, reported by 
more than 50% of HCV-infected patients.82-84 Fatigue does not appear to be associated with 
HCV RNA level, HCV genotype, or liver histology. In one study, HCV-associated fatigue was 
found to be associated with female gender and age >50 years.82 In addition to fatigue, impaired 
cognition is also reported, often referred to by HCV-infected patients as a feeling of “brain fog.” 
Indeed, studies have demonstrated mild but significant neurocognitive impairment in a 
proportion of HCV-infected patients with minimal or absent liver disease.85, 86 In one study, in an 
attempt to control for factors related to modes of HCV acquisition, Forton and co-workers 
compared HCV-infected viremic patients with histologically mild disease to patients with prior 
HCV infection who had cleared the virus.85 HCV-infected viremic patients demonstrated greater 
cognitive impairment on formal testing than those with resolved infection, and the deficits were 
shown specifically in concentration and speed of working memory. Since patients with advanced 
fibrosis or cirrhosis were excluded from the study, the impairments could not be accounted for 
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by mild hepatic encephalopathy. Moreover, the cognitive impairment was found to be 
independent of a history of substance abuse, depression, fatigue, or symptom severity. Thus, 
cognitive impairment appeared to be associated with the presence of HCV, independent of how 
the infection was acquired or the presence of other neuropsychiatric symptoms. 
 
Other studies have also demonstrated HCV-associated cognitive impairment, reporting deficits 
in measures of immediate and sustained attention, higher executive function, verbal learning 
ability, recall, and working memory.87 HCV-infected patients with mild liver disease showed 
deficits in attention and higher executive function compared with healthy controls, and the 
deficits were associated with fatigue severity.86 Although the HCV-infected patients in that study 
were also more depressed and anxious than the healthy controls, the selective nature of the 
cognitive deficits made it unlikely that the depression caused the cognitive impairment. 
Hilsabeck and co-workers found a significant relationship between cognitive test performance 
and fibrosis stage on liver biopsy in HCV-infected patients; however, patients with minor hepatic 
injury also demonstrated cognitive dysfunction in the attention and concentration domains, with 
impairment found in up to 50% of non-cirrhotic, HCV-infected individuals.7, 88 The pattern of 
impairment found was similar to that found in other studies, and was thought to be consistent 
with frontal–subcortical dysfunction, which parallels findings in HIV infection. Indeed, HCV 
infection appears to be an important independent factor for cognitive impairment in HCV–HIV 
co-infected individuals.87 For example, in a large prospective cohort of 526 patients, HIV, HCV, 
and methamphetamine use were independently associated with worse cognitive impairment, 
and higher HCV viral loads were positively correlated with impaired memory.89 
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In summary, a number of studies show that patients with histologically mild hepatitis C have 
evidence of cognitive impairment and exhibit symptoms of fatigue, and these neuropsychiatric 
manifestations appear to be independent of a history of substance abuse or the presence of 
mood disorders. Although HCV infection is often accompanied by advanced liver disease, illicit 
drug use, and other factors that may have additional effects on cognitive function, the reported 
findings suggest that HCV infection itself may have a direct biological effect on the central 
nervous system (CNS).  
 
Evidence for a biological effect on the CNS 
In order to determine whether a biological process underlies the neuropsychiatric symptoms and 
deficits associated with HCV, brain imaging has been employed. Using proton magnetic 
resonance spectroscopy (MRS), several groups have shown that HCV-infected patients with 
mild or absent liver disease and cognitive impairment have altered cerebral metabolism.85, 86, 90 
Cerebral proton MRS has shown that HCV-infected patients have elevated levels of choline in 
certain brain regions (basal ganglia, white matter, occipital grey matter) and reduced levels of N-
acetylaspartate compared with uninfected individuals.86, 90-92 These observed changes were not 
associated with the severity of liver disease and could not be attributed to hepatic 
encephalopathy. More recently, in separate studies by Bokemeyer and Forton, HCV-infected 
patients were shown to have elevated myoinositol:creatine ratios in the white matter that, in one 
study, were statistically correlated with impairments in working memory.92, 93 These findings 
strongly suggest that HCV infection causes brain dysfunction.  
 
One possible mechanism by which HCV may result in brain dysfunction is by inducing neuro-
inflammation. Elevated choline and myoinositol levels, demonstrated in the studies described 
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above, are also observed in neuro-inflammatory conditions such as multiple sclerosis or HIV 
infection of the brain, and are consistent with CNS glial cell proliferation and cell membrane 
injury, respectively.94 The altered cerebral metabolism observed in chronic hepatitis C patients 
suggests that active HCV infection might result in cerebral immune activation. Further evidence 
for this hypothesis comes from cerebral positron emission tomography (PET) imaging using 
PK11195, a ligand to the peripheral benzodiazepine receptor or translocator protein, which is 
expressed on activated microglia. In a study of patients with histologically mild HCV infection, 
PK11195 binding potential was significantly increased in the caudate nucleus of HCV-infected 
patients compared with healthy controls and this was positively correlated with viral load.95 The 
HCV-infected patients in this study also demonstrated elevated myoinositol:creatine and 
choline:creatine ratios compared with healthy controls. Thus, both altered cerebral metabolism 
and increased microglial activation were observed in patients with mild hepatitis C, and the 
microglial activation was associated with HCV viremia. These results may indicate that HCV in 
the CNS induces neuro-inflammation. Abnormalities in cerebral glucose metabolism and 
neurotransmission have also been reported in patients with non-cirrhotic HCV infection, 
suggesting that the neuro-inflammatory process leads to functional deficits.96, 97 
 
HCV may cause neuro-inflammation by penetrating the CNS and replicating in brain tissue. 
Evidence for this hypothesis comes from studies using molecular virology and laser capture 
micro-dissection techniques in autopsy samples.98, 99 In one study, HCV NS3 protein was found 
in brain microglia and, less often, in astrocytes.98 Viral sequences isolated from the CNS are 
distinct from those in serum and liver and share similarities from sequences associated with or 
isolated from peripheral blood mononuclear cells. Another study compared autopsy brain tissue 
from seven HCV-positive and eight HCV-negative patients and found that microglia of HCV-
positive patients expressed higher levels of pro-inflammatory cytokines than the HCV-negative 
controls; similarly, when microglia that co-stained for NS3 were compared with HCV-negative 
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cells in each of the seven HCV-positive patients, the NS3-positive cells expressed higher levels 
of pro-inflammatory cytokines.100 These data suggest that viral penetration into the CNS may 
directly result in microglial activation that in turn may trigger pathways that ultimately result in 
disturbances in neurotransmission. 
 
An alternative mechanism for the neuropsychiatric manifestations of HCV infection might be the 
effect of peripheral inflammation across the blood–brain barrier. Tryptophan, a serotonin 
precursor, is metabolized by the enzyme indoleamine-2-3-dioxygenase (IDO), producing 
kynurenine. IDO is activated by pro-inflammatory cytokines including the interferons, and its 
activity can be estimated by measuring the ratio of blood concentrations of kynurenine and 
tryptophan. Wichers and co-workers showed that in HCV-infected patients treated with 
interferon, the development of depressive symptoms is associated with elevated 
kynurenine:tryptophan ratios and the production of neurotoxic metabolites.101 Whether 
endogenous cytokines might have the same effect is not known, but in a pilot study of untreated 
HCV-infected patients, the kynurenine:tryptophan ratio was significantly elevated in fatigued 
patients compared with both HCV-infected, non-fatigued patients and uninfected controls.102 
 
The issue of extra-hepatic replication of HCV remains controversial, but recent work has shown 
that brain microvascular endothelial cells express all the receptors necessary for HCV infection 
and also permit HCV replication; the endothelial cells were shown to release infectious virus and 
to undergo conformational changes, which might allow viral passage across the blood–brain 
barrier.103 One hypothesis that may explain the findings to date is that HCV may infect the brain 
endothelium, resulting in apoptosis and a leaky blood–brain barrier, which in turn would allow 
peripheral cytokine and perhaps viral entry into the CNS (Figure 1A).104 Thus, the hypothesis is 
that HCV enters the brain and causes neuro-inflammation, leading to HCV-associated 
neuropsychiatric symptoms.  
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Consistent with the suggestion that there is a biological etiology for HCV-associated cognitive 
dysfunction, Kraus and co-workers showed that successful HCV eradication with peginterferon 
and ribavirin was associated with improved attention, vigilance, and working memory, while 
virologic non-responders showed no such improvements.105 These improvements in cognitive 
function were demonstrated one year after the end of treatment to control for the known effect of 
interferon-based treatment on brain function during the treatment period.106 Most recently, a pilot 
study in a small group of patients, using magnetic resonance spectroscopy, demonstrated 
normalization of cerebral N-acetyl aspartate, interpreted as recovery of neuronal dysfunction 
after successful antiviral treatment with interferon free treatment.107  
 
HCV, mixed cryoglobulinemia and non-Hodgkin’s lymphoma 
Shortly after the discovery of HCV, it was recognized that a high proportion of patients with 
mixed cryoglobulinemia (MC) were infected with the newly identified virus.108 Subsequent 
studies confirmed that up to 91% of patients with MC have active HCV infection.109, 110 
Circulating cryoglobulins are found in 40-60% of HCV-infected patients, however only 5-10% of 
these individuals develop clinical consequences.111 Clinical manifestations vary widely in 
prevalence and severity, with many patients having no symptoms and others presenting with 
life-threatening systemic vasculitis.  Cutaneous vasculitis with palpable purpura, often on the 
anterior aspect of the lower extremities, occurs in 18-33% and ranges from asymptomatic 
pigmentation from hemosiderosis related to past active small vessel vasculitis to aggressive 
cutaneous ulceration.17 Renal involvement with membranoproliferative glomerulonephritis (GN) 
occurs in about 27% of patients, ranging from mild proteinuria to progressive renal impairment.  
Other symptoms include neuropathy (11-30%), sicca syndrome (10-25%) and arthralgias (35-
54%), as well as non-specific features like fatigue (50%).112 
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Although there is accumulating evidence that HCV is able to infect and replicate in B cells, it is 
not clear that lymphocyte infection is required for MC to develop.113 Clonal expansion of B cells 
in response to viral antigens leads to production of rheumatoid factor-containing immune 
complexes, which cause symptomatic disease due to a complement C1q-mediated vasculitis 
upon deposition in small vessels of different organs (Figure 1B).17 Demonstration that the 
cryoprecipitate contains viral antigens, particularly the core protein, along with the expected 
monoclonal IgM, polyclonal IgG and complement proteins, furthered the evidence supporting a 
direct link between HCV and MC.17 HCV may stimulate B cell proliferation through direct 
interaction of the HCV E2 glycoprotein with CD81 on the surface of B cells or may directly bind 
to and activate HCV-specific B cell receptors.114 B cells in patients with MC demonstrate a 
restricted immunoglobulin heavy chain usage, with VH1-69 and VK3-20 highly over-
represented.10 Notably, these same clonal populations are found in patients with HCV-
associated NHL, suggesting a strong link between these two lymphoproliferative conditions.11 
However, even among patients with MC, NHL is rare, occurring at a rate of 6.6 per 1000 
person-years or lower, suggesting that NHL requires a second event beyond clonal B cell 
expansion.115 This is supported by careful evaluation of the B cell populations.  Patients with MC 
show expansion of peripheral IgM+κ+CD27+ B cells, characteristic of memory B cells.10 
Phylogenetic analysis suggests antigen-driven affinity maturation, supporting the concept that 
these cells are responding to viral antigens. 17 However, transcriptional analysis has shown that 
many of the B cells in MC patients display an anergic and pro-apoptotic phenotype, suggesting 
a loss of antigen-driven proliferation, possibly as a feedback mechanism to prevent auto-
reactive B cell responses and explaining the relatively low frequency of clinical manifestations in 
patients.116 Loss of the pro-apoptotic phenotype through specific gene translocations, 
stimulation by B cell activating factor and other mechanisms may lead MC to give rise to low-
grade NHL.112 HCV is also associated with aggressive diffuse large B cell NHL, however the 
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pathogenesis may differ with less evidence of antigen-driven proliferation and a greater 
association with direct viral infection of B cells.109, 110 
 
The strongest support for the relationship between HCV, MC and NHL is the response to 
antiviral therapy.  Interferon was first used to treat MC even before the discovery of HCV, with 
40-60% of patients showing on-treatment responses, however with this relatively ineffective 
antiviral regimen, relapse was common with recurrence of MC after stopping treatment. 17 With 
the introduction of peginterferon and ribavirin, rates of SVR increased and follow-up studies 
showed that 80-90% of patients had complete resolution of MC-related complications with 
successful viral eradication.17, 117 The persistence of MC after SVR may suggest that the 
process has become antigen-independent with continued activity due to persistent HCV 
antibodies despite viral clearance or possibly due to the transformation to low-grade NHL. The 
introduction of direct-acting antivirals holds great promise for the treatment of MC. An initial 
report of treatment with peginterferon, ribavirin and first-generation protease inhibitors in 
patients with MC found that all patients improved with therapy but notably only 70% of those 
who achieved SVR had a complete clinical response in terms of MC-related symptoms.  Even in 
the 10 patients who did not achieve SVR, 60% had a complete clinical response on therapy, but 
2 had a subsequent recurrence of vasculitis with viral relapse.118 
 
In patients who cannot tolerate or do not respond to antiviral therapy, immunosuppressive 
therapy may be required. Numerous uncontrolled studies have reported beneficial effects with 
glucocorticoids, azathioprine and other immunosuppressive regimens.17 With the clear 
relationship between MC and B cell populations, it was a logical step to evaluate anti-CD20 B 
cell-depleting agents.  Rituximab has been used alone, in combination with steroids and as an 
adjunct to antiviral therapy.17 The study designs and small sample sizes limit comparisons and 
strong conclusions but most data support that rituximab is effective in the majority of patients 
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and does not appear to negatively impact antiviral responses. For patients with severe, organ or 
life-threatening disease, plasmapheresis may be required along with B cell depleting therapy.  
Because of its immune-stimulatory effects, interferon may exacerbate some of the symptoms of 
MC vasculitis, limiting the tolerability of therapy. The introduction of interferon-free DAA 
regimens holds great promise for treating HCV-associated MC. 
 
Similar to MC, even low-grade NHL may respond to antiviral therapy.  The first description of 
regression of splenic lymphoma with villous lymphocytes with anti-HCV therapy was followed by 
other small series documenting regression or complete remission of HCV-associated NHL with 
antiviral therapy in a majority but not all patients.119 NHL remission has been reported in a small 
number of patients treated with interferon-free DAA-based regimens, suggesting that the effect 
is all virally-mediated and not due to anti-proliferative effects of interferon.120 At the population 
level, HCV therapy has also been shown to reduce the incidence of new onset NHL in Japan, 
making a case for consideration of earlier treatment, even in patients with limited liver disease to 
prevent future complications.121 In patients with high-grade NHL, primary treatment of the 
malignancy is required, however once remission is achieved, antiviral therapy should be 
introduced, as SVR markedly reduces and may even eliminate the risk of NHL relapse.122 It is 
possible that DAA therapies could be given with or even before chemotherapy for high-grade 
NHL, which may improve responses and are unlikely to affect tolerability. With the remarkable 
progress in HCV therapy, patients with evidence of MC, even if asymptomatic, may represent a 
population who should be prioritized for early antiviral therapy to prevent future symptomatic 
vasculitis and lymphoma. 
 
Miscellaneous manifestations 
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The array of extra-hepatic manifestations associated with HCV infection is large and 
heterogeneous. We will discuss selected ophthalmological, mucocutaneous and immunological 
manifestations not considered in the preceding paragraphs. 
 
Ophthalmological 
Two ophthalmological manifestations are noteworthy, i.e. Behçet disease and Mooren ulcer. In 
the case of Behçet disease, the causal link has never been convincingly proven,123 despite 
initial, isolated claims.124 On the other hand, good evidence associates Mooren-type peripheral 
ulcerative keratitis with HCV, since this rare condition has been reported to improve following 
interferon treatment.125 
 
Mucocutaneous 
The link between HCV and lichen planus is controversial, because most studies are 
retrospective, making it impossible to ascertain whether HCV infection has occurred before or 
after the appearance of the skin lesions. In patients with oral lichen planus, HCV was shown to 
replicate in the oral mucosa tissue.126 The affected oral mucosa may also harbor HCV-specific T 
lymphocytes,127 underlying the pathogenetic role of HCV. However, HCV does not seem to 
replicate in cutaneous lichen planus tissue,128 and the  effect of interferon therapy in such cases 
has been inconsistent, thus complicating the overall picture.129  
 
Pruritus has been reported to occur early in the natural history of hepatitis C.130 Pathogenesis 
may involve bile duct disappearance with ensuing low-grade cholestasis.131 However, in a case-
control study, the prevalence of HCV was not increased among patients with pruritus, and HCV 
represented only a minority of the potential causal agents of chronic itching, strongly suggesting 
that the systematic HCV screening in such cases is not indicated.132 
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Porphyria cutanea tarda (PCT) is the most common form of porphyria and in most cases 
recognizes exogenous causal agents, like iron overload, estrogen therapy, excess alcohol 
drinking and HCV infection.133 HCV is a very frequent cause of PCT: according to a meta-
analysis,134 as many as 50% of PCT patients may have markers of HCV infection, although a 
wide geographical variation in prevalence suggests that other cofactors (genetic and/or 
environmental) may play a role in the pathogenesis and phenotypic expression of PCT. The 
central pathogenetic events seem to involve iron overload and oxidative stress. Although 
traditionally PCT has been managed by phlebotomy, the best approach is the elimination of the 
causal agent. Therapy with interferon and ribavirin may exacerbate PCT manifestations, 
including appearance of blisters in the sun-exposed areas, milia, hirsutism and skin erosions. 
Thus, patients with PCT may particularly benefit from interferon-free regimens. 
 
Immunological disorders 
One of the most intruiguing and debated association between HCV and immunological 
disorders concerns rheumatoid arthritis. A recent, large population-based cohort study assessed 
the risk of rheumatoid arthritis in patients with a chronic infection with HCV or HBV.135 A total of 
35,652 persons had HBV infection alone, 10,253 had HCV infection, and 3,987 had chronic 
HBV/HCV dual infections. These were matched with 199,568 uninfected controls and followed 
for a decade. After adjusting for covariates, chronic HCV infection alone was significantly 
associated with an increased risk for rheumatoid arthritis (HR  = 2.03, 95% CI = 1.27-3.22), a risk 
not shared by carriers of HBV. Convincing, conclusive data on the beneficial effect of antiviral 
therapy (if any) are not available. 
 
Idiopathic pulmonary fibrosis is another rare but serious condition that has been associated with 
HCV infection. In a large retrospective series,  the incidence of pulmonary fibrosis was 
significantly higher among HCV patients than in HBV infected controls.136 Risk factors for the 
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development of pulmonary fibrosis were age, smoking and cirrhosis. This condition should not 
be banalized as it can be dramatically exacerbated by interferon therapy.137  
 
Thyroid autoimmune stigmata are relatively frequent in chronic hepatitis C, and may 
occasionally be associated with hypofunction. A genetic predisposition has been invocated, as 
these disorders seem to affect predominantly females with haplotype HLA DR-3.138 Interferon 
alpha therapy can exacerbate this disorder; hyperthyroidism and hypothyroidism are equally 
observed in patients receiving interferon, with some experiencing permanent sequelae. Again, 
these patients may benefit from the advent of interferon-free regimens. 
 
Finally, a troublesome association has been reported between  HCV infection and some severe 
autoimmune cytopenias,139 including autoimmune hemolytic anemia and autoimmune 
thrombocytopenic purpura. Interferon is mostly contraindicated in these patients, and, 
depending on the severity of the deficit, treatment requires use of corticosteroids, intravenous 
immunoglobulins or splenectomy. In the rare cases where interferon is permitted, the cytopenia 
may remit. These conditions are clearly the ultimate candidates to interferon-free regimens. 
 
Evolving risks and benefits of HCV eradication in the era of DAAs 
The availability of well-tolerated, interferon-free, DAA regimens for the treatment of chronic HCV 
infection will significantly broaden the spectrum of patients eligible for and willing to undergo 
anti-HCV treatment. Until recently, therapy may not have been indicated for patients at low risk 
of liver disease progression due to the numerous side effects. In particular, immune stimulation 
induced by interferon has been a deterrent to treat hepatitis C patients with various 
immunological manifestations. Further, patients with comorbid conditions such as depression, 
cardiovascular disease, and/or severe fatigue were typically considered poor candidates for 
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treatment with interferon-alpha since this drug could worsen such conditions. The recent 
introduction of more tolerable, more effective therapies has significantly broadened the 
spectrum of HCV-infected patients who can be considered candidates for treatments aimed at 
HCV eradication, including those who were interferon-ineligible or -intolerant, or who have a low 
or moderate risk of liver disease progression, or who experience mainly the extra-hepatic effects 
of HCV.22 140, 141 
 
Studies demonstrating that successful HCV treatment may reduce non-hepatic mortality lend 
credence to the concept of broader treatment indications. In a long-term study of 530 patients 
with advanced fibrosis or cirrhosis, SVR was associated with significantly reduced all-cause 
mortality.9 Other studies have also shown the extra-hepatic benefits of HCV eradication (Table 
3): patients with SVR following peginterferon and ribavirin have reduced steatosis, a lower 
incidence of malignant lymphoma,121 reduced risk of type 2 diabetes142 and insulin resistance,38, 
39, 143-145
 improved cognitive performance,105 reduction in fatigue,146, 147 improvement in 
myocardial perfusion defects,75 reduced incidence of stroke,76 reduced renal and cardiovascular 
outcomes in the presence of diabetes,51 complete resolution of MC-related complications,17, 117 
and regression or complete remission of HCV-associated lymphoma.119 It is also clear that 
interferon and ribavirin-free treatment results in improved patient-reported outcomes in many 
patient groups, after as early as two weeks of treatment. Clinically important gains in quality of 
life are associated with SVR.20, 21 Thus, multiple studies have demonstrated that durable HCV 
eradication achieved with interferon-based therapies improves both liver-related and non-liver-
related outcomes.  
 
The availability of safe and well tolerated interferon-free regimens will enable the treatment of 
more patients, including those subgroups with immunological and psychiatric manifestations in 
whom interferon was generally contraindicated.148-152  Indeed, clinical studies have already 
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assessed changes in extra-hepatic manifestations of HCV during treatment with new DAA 
regimens. For example, SVR achieved after treatment with sofosbuvir, including one interferon-
free regimen, was associated with improvements in central fatigue153 and in HRQL.154 Data from 
these studies also show that patient-reported outcomes and HRQL are better during treatment 
with interferon-free DAA regimens than during treatment with interferon-containing regimens.153, 
154
 Thus, the evidence is mounting that viral eradication is indeed associated with an 
amelioration of an increasing number of extrahepatic manifestations associated with HCV, 
providing, apart from a clear benefit for the patient, also the support for a pathogenetic link. Not 
surprisingly, major clinical practice guidelines of international societies have already 
incorporated the presence of extrahepatic manifestations – including e.g. debilitating fatigue – 
as a priority indication for treatment with the novel interferon-free regimens, even in the absence 
of significant liver damage. However, the long-term benefit of SVR in these patients, such as the 
prevention of NHL in patients with cryoglobulinemia, can only be proven by large, prospective 
trials.  
 
In conclusion, the involvement of non-hepatic organ systems in HCV infection substantially 
decreases the quality of life of chronically infected patients, and may also increase non-hepatic 
mortality. Viral eradication reduces extra-hepatic manifestations of HCV, and improved cure 
rates with new regimens will conceivably result in even more marked effects. Since these new 
regimens are also better tolerated than previously available treatments and have an improved 
risk–benefit profile, extra-hepatic manifestations of HCV form an important indication for anti-
HCV treatment, even in the absence of liver disease. 
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Tables 
Table 1. Metabolic effects of HCV infection 
Potential effect Studies and main findings Reference  
Diabetes mellitus 
Mehta 2000: Based on NHANES data collected between 1988 
and 1994, among patients 40 years and older, HCV infection was 
associated with diabetes (OR 3.77, 95% CI 1.80–7.87)   
5
 
Wang 2007: Compared with uninfected individuals, HCV-
infected patients had a higher cumulative incidence of diabetes 
(HR 1.7, 95% CI 1.3–2.1) in a community-based, longitudinal 
study 
6
 
Mehta 2003: Among patients at high risk for diabetes, HCV 
infection increased the risk of diabetes more than 11-fold during 
9 years of follow-up (HR 11.58, 95% CI 1.39–96.6) 
23
 
Younossi 2013: Based on NHANES data collected between 1999 
and 2010, chronic HCV infection was independently associated 
with diabetes (OR=2.31, 95% CI 1.18–4.54), insulin resistance 
(OR=2.06, 95% CI 1.19–3.57), and hypertension (OR=2.06, 95% 
CI 1.30–3.24) 
28
 
White 2008: HCV-infected patients had significantly higher risk 
of diabetes compared with uninfected controls and compared 
with HBV-infected controls in a meta-analysis 
24
 
Insulin resistance  
Younossi 2013: Based on NHANES data collected between 1999 
and 2010, chronic HCV was independently associated with 
diabetes (OR=2.31, 95% CI 1.18–4.54), insulin resistance 
(OR=2.06, 95% CI 1.19–3.57), and hypertension (OR=2.06, 95% 
CI 1.30–3.24) 
28
 
Moucari 2008: Insulin resistance (HOMA-IR) was present in 35% 
of HCV-infected vs 5% of HBV-infected patients, and was 
associated with HCV genotypes 1 and 4, high viral load, and liver 
fibrosis  
29
 
Vanni 2009: Patients with chronic HCV infection and no features 
of the metabolic syndrome (n=14) showed increased peripheral 
and hepatic insulin resistance compared with healthy controls 
(n=7); hepatic insulin resistance index was increased 3-fold in 
HCV-infected patients compared with controls 
34
 
Milner 2010: Insulin resistance was significantly increased in 
non-obese, HCV-infected male patients compared with healthy 
controls; insulin resistance was principally peripheral rather 
than hepatic, most likely in muscle 
40
 
Muzzi 2005: HOMA-IR score was associated with fibrosis in HCV-
infected patients 
36
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Lecube 2006: In a case-control study, HOMA-IR score was 
significantly higher in HCV-infected patients than in controls 
with chronic hepatitis other than HCV 
155
 
BMI, body-mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; HOMA-IR, homeostasis 
model for assessment of insulin resistance; HR, hazard ratio; NHANES, national health and 
nutrition examination survey; OR, odds ratio 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
30 
 
Table 2. Neurologic effects of HCV infection  
Potential effect Studies and main findings Reference 
Fatigue 
 
Foster 1998: HCV-infected patients had a significantly 
reduced quality of life compared with uninfected and with 
HBV-infected controls, as measured by physical functions 
(fatigue, energy, body pain) assessed using the Short Form 36 
(SF-36) symptomatology questionnaire  
80
 
Poynard 2002: Fatigue was present in 53% of HCV-infected 
patients and was associated with female gender, age >50 
years, cirrhosis, depression, and purpura 
82
 
Cacoub 2002: Fatigue was present in 59% of chronic hepatitis 
C patients 
83
 
Stefanova-Petrova 2007: Fatigue was present in 60% of HCV-
infected patients 
84
 
Tillmann 2011: Two independent prospective cross-sectional 
studies of 511 and 284 patients with different forms of liver 
disease showed reduced mental quality of life in HCV-
infected patients 
81
 
Cognitive 
impairment 
 
 
Forton 2002: Chronic hepatitis C patients with detectable HCV 
RNA and histologically mild disease were cognitively impaired 
compared with previously infected patients who had cleared 
the virus, and compared with healthy controls; HCV-infected 
patients were significantly impaired on tests of concentration 
and speed of memory processes 
85
 
Weissenborn 2004: HCV-infected patients with mild liver 
disease demonstrated impairment in attention and higher 
executive function compared with healthy controls 
86
 
Hilsabeck 2002 and 2003: Cognitive impairment in HCV 
patients was related to severity of liver disease but was also 
evident in patients without cirrhosis 
7, 88
 
Letendre 2005: HIV, HCV, and methamphetamine use were 
independently associated with cognitive impairment in HCV–
HIV co-infected patients 
89
 
Weissenborn 2006: Decreased serotonin and dopamine 
transporter binding, measured by single photon emission 
computerized tomography, was associated with impaired 
performance on psychometric testing 
96
 
Forton 2008: Impairments in working memory correlated 
with white matter myonositol:creatine ratios, measured by 
cerebral magnetic resonance spectroscopy 
93
 
HBV, hepatitis B virus; HCV, hepatitis C virus 
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Table 3. Benefits associated with eradication of HCV infection  
Condition Studies and main findings Reference 
Insulin resistance 
Kawaguchi 2007: Chronic HCV-infected patients treated with 
interferon-alpha with or without ribavirin who achieved SVR 
had significantly reduced HOMA-IR values while virologic non-
responders and relapsers showed no change in HOMA-IR  
38
 
Milner 2014: Chronic HCV-infected patients (n=8) in whom 
HCV was eradicated following antiviral therapy had reduced 
peripheral insulin resistance compared with baseline; insulin 
sensitivity following viral eradication was comparable to 
matched uninfected controls  
145
 
Moucari 2010: Decline in serum HCV RNA correlated with 
reduction in HOMA-IR during 14 days of monotherapy with 
the NS3 inhibitor danoprevir, compared with HCV RNA and 
HOMA-IR which remained unchanged in placebo-treated 
patients  
39
 
Diabetes 
Arase 2009: In a retrospective study, SVR following treatment 
with interferon or interferon plus ribavirin conferred a 
reduced risk (by about two thirds) of developing type 2 
diabetes, even after stratification according to age, cirrhosis 
and prediabates 
142
 
Stroke 
Hsu 2013: In a retrospective cohort study, HCV-infected 
patients who received interferon-based therapy had a 
significantly reduced risk of stroke compared with untreated 
patients (adjusted HR 0.39, 95% CI 0.16–0.95) 
76
 
Myocardial 
perfusion defects 
Maruyama 2013: Myocardial perfusion defects, found in the 
majority of HCV-infected patients, improved after interferon 
treatment in patients with SVR; did not change in non-
responders; and temporarily improved, then returned to 
baseline in relapsers 
75
 
Fatigue and 
HRQL 
Cacoub 2002: Achieving SVR was associated with reduction in 
fatigue after adjusting for age, gender, fibrosis stage, and 
depression (OR 0.34, p<0.001) 
83
 
Hassanein 2004: HCV-infected patients who achieved SVR 
with peginterferon plus ribavirin or interferon-alpha plus 
ribavirin demonstrated significant improvement in HRQL, as 
assessed by the 36-item Short Form Health Survey (SF-36) 
and the Fatigue Severity Scale (FSS)  
146
 
Rasenack 2003: HCV-infected patients who achieved SVR 
following 48 weeks of peginterferon or interferon-alpha had 
significantly improved HRQL compared with those without 
SVR, as measured by mean SF-36 scores and mean FSS scores 
147
 
Younossi 2014: HCV genotype 2 or 3-infected patients treated 
with sofosbuvir and ribavirin who achieved SVR had 
significant improvements from baseline in HRQL, as 
measured by fatigue, SF-36 score, emotional well-being, 
153
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general health, and results of the Chronic Liver Disease 
Questionnaire-HCV 
Cognitive 
function 
Kraus 2013: HCV-infected patients with SVR after treatment 
with peginterferon and ribavirin demonstrated significant 
improvement in neurocognitive function when tested at least 
one year after the end of therapy; patients without SVR 
showed no changes in neurocognitive function  
105
 
Cerebral 
magnetic 
resonance 
spectroscopy  
Alsop DY 2014: HCV patients after treatment with ledipasvir-
sofosbuvir demonstrated increases in cerebral N-acetyl 
aspartate, interpreted as recovery of neuronal dysfunction 
107
 
Mixed 
cryoglobulinemia 
Gragnani L 2015: HCV-infected patients with MC treated with 
peginterferon and ribavirin showed a good clinico-
immunological correlation with SVR, since all patients with 
SVR also experienced a sustained clinical response, either 
complete or partial, while all virological nonresponders were 
also clinical nonresponders, despite a transient improvement 
in some patients 
117
 
Saadoun D 2015: 30 patients with hepatitis C and MC – 
mostly previous noresponsders – were retreated with  
peginterferon and ribavirin plus a protease inhibitor 
(telaprevir or boceprevir), with a high rate of both clinical and 
virological success, in spite of side effects 
118
 
Lymphoma 
Hermine O 2002: In nine patients with HCV infection treated 
with interferon alfa, seven had a complete remission of 
splenic lymphoma with villous lymphocytes upon virological 
response, while the remaining 2 patients had a partial and a 
complete remission after the addition of ribavirin and 
disappearance of HCV RNA. One patient had a relapse when 
the HCV RNA load again became detectable after therapy  
119
 
Carrier P 2015: Five patients with HCV-associated B cell non 
Hodgkin lymphoma were treated with DAA (one received also 
rituximab and two chemotherapy in addition to DAA). SVR 
was reached in all, and complete remission of NHL was noted 
six months after cessation of treatment (except in one patient 
who had a persistent small leukemic phase) 
120
 
Kawamura Y 2007: In a retrospective study, 501 untreated 
and 2708 HCV-infected patients treated with interferon were 
followed up to 15 years. In untreated cases, a malignant 
lymphoma developed in 0.6% at the 5th year, 2.3% at the 
10th year, and 2.6% at the 15th year. The rates in treated 
patients with SVR were 0% up to 15th year, while in those 
treated but not cured the rate incresaed up to 2.6% at the 
15th year 
121
 
La Mura V 2008: In 69 HCV-infected patients with 
lymphomas, antiviral therapy carried out after chemotherapy 
(n=25) was associated with an increased disease-free survival. 
122
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None of the SVR experienced a lymphoma relapse, while 29% 
of non-responders did 
Mortality  
Van der Meer 2012: In HCV-infected patients with advanced 
fibrosis or cirrhosis, achieving SVR with interferon-based 
therapy was associated with reduced all-cause mortality 
9
 
 
FSS, Fatigue Severity Scale; HCV, hepatitis C virus; HOMA-IR, homeostasis model for assessment of 
insulin resistance; HR, hazard ratio; HRQL, health-related quality of life; OR, odds ratio; SF-36, Short 
Form Health Survey; SVR, sustained virologic response 
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Figures  
Figure 1. HCV interactions with vascular endothelium. A. Brain microvascular endothelial cells 
express all the receptors for HCV infection and are permissive to viral replication.103 Infected 
endothelial cells may undergo apoptosis, inducing a conformational change, allowing a breach 
of the blood brain barrier. Circulating cytokines, free virus and possibly infected PBMC may 
passage into the CNS, leading to microglial activation and neuronal dysfunction. B. 
Cryoglobulinaemia. HCV viral particles and core protein bind to marginal zone B cells. 
Stimulated by B cell-activating factor, released from activated dendritic cells, there is clonal 
expansion of B cells leading to the release of large amounts of IgM with rheumatoid (RF) 
activity. IgM RF molecules form complexes with HCV viral particles to form cold-precipitable 
immune complexes, which accept the C1q protein and bind to vascular endothelial cells, 
stimulating the complement system, generating vasoactive peptides and the recruitment of 
neutrophils leading to a leukocytoplastic vasculitis. 
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